FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel arylpyrimidine compounds of the formula (I) 
showing effect of an antagonist of 5HT2B-receptor and to a pharmaceutical composition. In compounds of the formula (I) R1 means hydrogen atom, C1-C12-alkyl, hydroxy-C1-C12-alkyl, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C6-alkyl, C2-C12-alkenyl, C1-C6- thioalkoxy-group, halogen atom, fluoro-C1-C12-alkyl, phenyl-C1-C6-alkyl optionally substituted with C1-C6-alkyl, C1-C6-alkoxy-group, hydroxy-group, nitro-group, C1-C6-fluoroalkyl and halogen atom; NR6R7,-CO2R8 or -O(CH2)nR9 where n = 1, 2 or 3; R6 and R7 mean independently each of other hydrogen atom or C1-C6-alkyl; R8 means hydrogen atom or C1-C6-alkyl; R9 means hydrogen atom, C1-C6- alkyl, hydroxy-group, hydroxy-C1-C6-alkyl, C2-C6-alkenyl or C1-C6-alkoxy-group; R2 means hydrogen atom, C1-C6-alkyl, halogen atom or C1-C6-fluoroalkyl; R3 means phenyl, thiophene, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, 1,2,3,4- tetrahydroquinoline, indole, 2,3-dihydroindole, 1H-benzo[b] azepine, 2,3,4,5-tetrahydro-1H-benzo[b] azepine, 2H-benzo[1,4]oxazine, 3,4-dihydro-2H-benzo[1,4] -oxazine, 1H,3H- benzo[d,e]isochromen, 6,7,8,9-tetrahydro-5-oxa-9-benzocyclopentane, 2,3-dihydro-1,4-benzodioxane optionally substituted with C1-C6/ -alkyl, C1-C6-alkoxy-group, hydroxy-group, nitro-group, C1-C6-fluoroalkyl and halogen atom; 
means hydrogen atom, C1-C6-alkyl, phenyl-C1-C6-alkyl optionally substituted with C1-C6- alkyl, C1-C6-alkoxy-group, hydroxy-group, nitro-group, C1-C6-fluoroalkyl and halgen atom; hydroxy-C1-C6-alkyl, C(O)-C1-C6-alkyl or -(CH2)mNR6R7 where m is a whole number from 1 to 6; R6 and R7 mean hydrogen atom or C1-C6- alkyl; R5 means hydrogen atom or C1-C6-alkyl under condition that: (1) when R3 means naphthyl, indole-1- yl or 2,3-dihydroindole-1-yl and R2,R4,R5 all mean hydrogen atom then R1 does not mean methyl; (2) when R3 means phenyl or naphthyl then R1 does not mean -NR6R7; (3) when R3 means phenyl then R2 does not mean C1-C6-alkoxy-group and R1 and R2 do not mean halogen atom; (4) when R3 means phenyl and R1 means H then R2 does not mean methyl and (5) when R3 means 1,2,3,4-tetrahydroquinolinyl then R4 and R5 mean hydrogen atom, or its pharmaceutically acceptable salt or N-oxide. Pharmaceutical composition comprises therapeutically effective amount of compound of the formula (I) and one or some pharmaceutically acceptable nontoxic carriers. Indicated compounds and pharmaceutical composition can be used as an antiallergic, antiasthmatic, anti-inflammatory agents and in diseases of gastroenteric tract also. EFFECT: new compounds indicated above, valuable medicinal properties. 16 cl, 12 sch, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF THIAZOLE, METHOD OF THEIR SYNTHESIS, COMPOSITION BASED ON THEREOF AND INTERMEDIATE COMPOUND | 1999 |
|
RU2166503C2 |
| PIRAZOLOIMIDAZOPYRIMIDINE DERIVATIVES WITH ANTAGONIST ACTIVITY TO CORTICOTROPHIN RELEASE FACTOR (CRF) | 2004 |
|
RU2377241C2 |
| PYRIMIDINE DERIVATIVES WITH INHIBITING ACTION WITH RESPECT TO 11b-HSD1 | 2005 |
|
RU2375351C2 |
| DERIVATIVES OF 5H-THIAZOL[3,2-A]PYRIMIDINE, INTERMEDIATE COMPOUNDS AND MEDICINAL AGENT | 1998 |
|
RU2197493C2 |
| BENZENESULFONE DERIVATIVES AND MEDICINAL AGENT | 1999 |
|
RU2201922C2 |
| SULFONEAMIDE DERIVATIVES AND PHARMACEUTICAL PREPARATION | 1996 |
|
RU2173317C2 |
| THIAZOLE DERIVATIVES, METHOD FOR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1999 |
|
RU2214404C2 |
| PYRAZOLO[1,5-A]PYRIMIDINES AND PYRAZOLO[1,5-A]- TRIAZINES AND MEDICINAL AGENTS | 1999 |
|
RU2218340C2 |
| SULFAMIDES AND THEIR USING | 1997 |
|
RU2192257C2 |
| RETINOIC ACID X-RECEPTOR LIGANDS | 1995 |
|
RU2146241C1 |
